

Yogendra Kanthi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5105498/publications.pdf>

Version: 2024-02-01

47
papers

3,906
citations

257357

24
h-index

265120

42
g-index

53
all docs

53
docs citations

53
times ranked

6897
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Medical Therapy Following Deep Venous Interventions: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 78-85.	0.2	6
2	Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. <i>Blood Cancer Journal</i> , 2022, 12, 28.	2.8	31
3	Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. <i>Seminars in Immunopathology</i> , 2022, 44, 347-362.	2.8	67
4	Endothelial Cell-Activating Antibodies in COVID-19. <i>Arthritis and Rheumatology</i> , 2022, 74, 1132-1138.	2.9	47
5	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 1603-1604.	2.9	0
6	Neutrophil extracellular traps and thrombosis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 446-453.	1.0	201
7	Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. <i>Journal of Leukocyte Biology</i> , 2021, 109, 67-72.	1.5	107
8	Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 1580.	1.6	175
9	The interplay between neutrophils, complement, and microthrombi in COVID-19. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101661.	1.4	35
10	Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021, 28, 3125-3139.	5.0	189
11	At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 342-349.	1.2	9
12	Autoantibodies stabilize neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2021, 6, .	2.3	53
13	Inflammation, Infection and Venous Thromboembolism. <i>Circulation Research</i> , 2021, 128, 2017-2036.	2.0	94
14	Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide. <i>JCI Insight</i> , 2021, 6, .	2.3	23
15	Thrombotic manifestations of VEXAS syndrome. <i>Seminars in Hematology</i> , 2021, 58, 230-238.	1.8	24
16	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	138
17	SARS-CoV-2 Spike Protein S1-Mediated Endothelial Injury and Pro-Inflammatory State Is Amplified by Dihydrotestosterone and Prevented by Mineralocorticoid Antagonism. <i>Viruses</i> , 2021, 13, 2209.	1.5	36
18	VITT(al) insights into vaccine-related clots. <i>Blood</i> , 2021, 138, 2159-2160.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	491
20	COVID-19-associated coagulopathy: An exploration of mechanisms. <i>Vascular Medicine</i> , 2020, 25, 471-478.	0.8	215
21	Shining a Light on Venous Thromboembolism. <i>JACC Basic To Translational Science</i> , 2020, 5, 357-359.	1.9	0
22	Nanotherapeutic Shots through the Heart of Plaque. <i>ACS Nano</i> , 2020, 14, 1236-1242.	7.3	24
23	Diagnostic approach and management of genetic aortopathies. <i>Vascular Medicine</i> , 2020, 25, 63-77.	0.8	19
24	Neutrophil extracellular traps in COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	988
25	New (re)purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm. <i>JCI Insight</i> , 2020, 5, .	2.3	36
26	Vascular medicine and social media, highlights from the practice and compensation survey, and the future of vascular medicine training. <i>Vascular Medicine</i> , 2019, 24, 375-379.	0.8	5
27	Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. <i>Nature Communications</i> , 2019, 10, 1916.	5.8	152
28	Tuning the Thromboinflammatory Response to Venous Flow Interruption by the Ectonucleotidase CD39. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, e118-e129.	1.1	16
29	ENTPD-1 disrupts inflammasome IL-1 β -driven venous thrombosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 2872-2877.	3.9	75
30	Distal radial and ulnar artery thrombosis in a cancer patient with a history of chronic handgun use. <i>Vascular Medicine</i> , 2018, 23, 84-85.	0.8	0
31	Ectonucleotidase-Mediated Suppression of Lupus Autoimmunity and Vascular Dysfunction. <i>Frontiers in Immunology</i> , 2018, 9, 1322.	2.2	19
32	Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1632-1643.	1.1	31
33	Great Debates in Vascular Medicine: Extended duration anticoagulation for unprovoked venous thromboembolism – Coming to consensus when the debate rages on. <i>Vascular Medicine</i> , 2018, 23, 384-387.	0.8	6
34	Ruptured external jugular varix. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 121-123.	0.9	1
35	Ischemic Cerebroprotection Conferred by Myeloid Lineage-Restricted or Global CD39 Transgene Expression. <i>Circulation</i> , 2017, 135, 2389-2402.	1.6	24
36	Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4487-4496.	1.4	52

#	ARTICLE	IF	CITATIONS
37	In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 655-667.	2.9	166
38	Endotoxaemia-augmented murine venous thrombosis is dependent on TLR-4 and ICAM-1, and potentiated by neutropenia. <i>Thrombosis and Haemostasis</i> , 2017, 117, 339-348.	1.8	28
39	Ectonucleotidase CD39-driven control of postinfarction myocardial repair and rupture. <i>JCI Insight</i> , 2017, 2, e89504.	2.3	20
40	Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis. <i>Journal of Vascular Research</i> , 2016, 53, 186-195.	0.6	8
41	Purinergic dysregulation in pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H286-H298.	1.5	35
42	Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. <i>Vascular Medicine</i> , 2015, 20, 143-152.	0.8	25
43	Flow-dependent expression of ectonucleotide tri(di)phosphohydrolase-1 and suppression of atherosclerosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 3027-3036.	3.9	47
44	Venous thromboembolism: Diagnosis, treatment and the prevention of long-term complications. <i>Reviews in Vascular Medicine</i> , 2014, 2, 136-142.	0.4	0
45	Regulation of ecto-ATPase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3). <i>FASEB Journal</i> , 2013, 27, 4419-4428.	0.2	20
46	Successful Combined Use of Impella Recover 2.5 Device and Intra-Aortic Balloon Pump Support in Cardiogenic Shock from Acute Myocardial Infarction. <i>ASAIO Journal</i> , 2010, 56, 519-521.	0.9	16
47	Acute profound thrombocytopenia with second exposure to eptifibatide associated with a strong antibody reaction. <i>Platelets</i> , 2009, 20, 64-67.	1.1	11